Bruker (NASDAQ:BRKR) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Bruker Co. (NASDAQ:BRKR) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $61.87 and traded as high as $62.46. Bruker shares last traded at $61.25, with a volume of 867,430 shares traded.

Analyst Ratings Changes

Several equities research analysts have weighed in on BRKR shares. Citigroup lowered their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Barclays lowered their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. TD Cowen decreased their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Wells Fargo & Company lowered their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Finally, UBS Group started coverage on shares of Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Bruker currently has an average rating of “Moderate Buy” and a consensus target price of $74.45.

Bruker Stock Up 1.0 %

The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The business’s 50-day simple moving average is $57.63 and its 200-day simple moving average is $61.87. The company has a market capitalization of $9.29 billion, a PE ratio of 29.45, a price-to-earnings-growth ratio of 4.00 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same period last year, the business earned $0.74 EPS. As a group, equities research analysts anticipate that Bruker Co. will post 2.4 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.33%. The ex-dividend date was Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is 9.62%.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were bought at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 28.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

A number of large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its position in shares of Bruker by 0.8% in the second quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company’s stock valued at $1,972,000 after purchasing an additional 235 shares during the period. US Bancorp DE lifted its stake in Bruker by 2.1% in the 3rd quarter. US Bancorp DE now owns 12,700 shares of the medical research company’s stock valued at $877,000 after buying an additional 260 shares in the last quarter. Coldstream Capital Management Inc. boosted its holdings in Bruker by 7.3% in the 3rd quarter. Coldstream Capital Management Inc. now owns 4,553 shares of the medical research company’s stock worth $312,000 after buying an additional 308 shares during the last quarter. National Bank of Canada FI increased its stake in Bruker by 0.3% during the 3rd quarter. National Bank of Canada FI now owns 94,867 shares of the medical research company’s stock worth $6,551,000 after buying an additional 318 shares in the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Bruker by 23.7% during the third quarter. Assetmark Inc. now owns 1,729 shares of the medical research company’s stock valued at $119,000 after acquiring an additional 331 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.